ESPR Quote, Financials, Valuation and Earnings

Heron Therapeutics has a net margin of -30.85% compared to Esperion Therapeutics's net margin of 8.98%. Esperion Therapeutics's return on equity of -- beat Heron Therapeutics's return on equity of --.

Esperion Therapeutics has a consensus price target of $6.12, signalling upside risk potential of 512.51%. On the other hand Heron Therapeutics has an analysts' consensus of $6.33 which suggests that it could grow by 170.66%. Given that Esperion Therapeutics has higher upside potential than Heron Therapeutics, analysts believe Esperion Therapeutics is more attractive than Heron Therapeutics.

Esperion Therapeutics has a beta of 0.749, which suggesting that the stock is 25.126% less volatile than S&P 500. In comparison Heron Therapeutics has a beta of 1.393, suggesting its more volatile than the S&P 500 by 39.337%.

Esperion Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Heron Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Esperion Therapeutics pays -- of its earnings as a dividend. Heron Therapeutics pays out -- of its earnings as a dividend.

Esperion Therapeutics quarterly revenues are $69.1M, which are larger than Heron Therapeutics quarterly revenues of $40.8M. Esperion Therapeutics's net income of -$21.3M is lower than Heron Therapeutics's net income of $3.7M. Notably, Esperion Therapeutics's price-to-earnings ratio is -- while Heron Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Esperion Therapeutics is 0.58x versus 2.47x for Heron Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -30.85% compared to Esperion Therapeutics's net margin of -49.65%. Esperion Therapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Esperion Therapeutics has a consensus price target of $6.12, signalling upside risk potential of 512.51%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 45.3%. Given that Esperion Therapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Esperion Therapeutics is more attractive than NovaBay Pharmaceuticals.

Esperion Therapeutics has a beta of 0.749, which suggesting that the stock is 25.126% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

Esperion Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Esperion Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Esperion Therapeutics quarterly revenues are $69.1M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Esperion Therapeutics's net income of -$21.3M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Esperion Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Esperion Therapeutics is 0.58x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics has a net margin of -30.85% compared to Esperion Therapeutics's net margin of --. Esperion Therapeutics's return on equity of -- beat Plus Therapeutics's return on equity of --.

Esperion Therapeutics has a consensus price target of $6.12, signalling upside risk potential of 512.51%. On the other hand Plus Therapeutics has an analysts' consensus of $9.63 which suggests that it could grow by 1151.46%. Given that Plus Therapeutics has higher upside potential than Esperion Therapeutics, analysts believe Plus Therapeutics is more attractive than Esperion Therapeutics.

Esperion Therapeutics has a beta of 0.749, which suggesting that the stock is 25.126% less volatile than S&P 500. In comparison Plus Therapeutics has a beta of 0.675, suggesting its less volatile than the S&P 500 by 32.459%.

Esperion Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Esperion Therapeutics pays -- of its earnings as a dividend. Plus Therapeutics pays out -- of its earnings as a dividend.

Esperion Therapeutics quarterly revenues are $69.1M, which are larger than Plus Therapeutics quarterly revenues of --. Esperion Therapeutics's net income of -$21.3M is lower than Plus Therapeutics's net income of -$2.9M. Notably, Esperion Therapeutics's price-to-earnings ratio is -- while Plus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Esperion Therapeutics is 0.58x versus 0.95x for Plus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Xeris Biopharma Holdings has a net margin of -30.85% compared to Esperion Therapeutics's net margin of -8.51%. Esperion Therapeutics's return on equity of -- beat Xeris Biopharma Holdings's return on equity of -1019.2%.

Esperion Therapeutics has a consensus price target of $6.12, signalling upside risk potential of 512.51%. On the other hand Xeris Biopharma Holdings has an analysts' consensus of $6.08 which suggests that it could grow by 41.72%. Given that Esperion Therapeutics has higher upside potential than Xeris Biopharma Holdings, analysts believe Esperion Therapeutics is more attractive than Xeris Biopharma Holdings.

Esperion Therapeutics has a beta of 0.749, which suggesting that the stock is 25.126% less volatile than S&P 500. In comparison Xeris Biopharma Holdings has a beta of 1.094, suggesting its more volatile than the S&P 500 by 9.436%.

Esperion Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xeris Biopharma Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Esperion Therapeutics pays -- of its earnings as a dividend. Xeris Biopharma Holdings pays out -- of its earnings as a dividend.

Esperion Therapeutics quarterly revenues are $69.1M, which are larger than Xeris Biopharma Holdings quarterly revenues of $60.1M. Esperion Therapeutics's net income of -$21.3M is lower than Xeris Biopharma Holdings's net income of -$5.1M. Notably, Esperion Therapeutics's price-to-earnings ratio is -- while Xeris Biopharma Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Esperion Therapeutics is 0.58x versus 3.19x for Xeris Biopharma Holdings. Usually stocks with elevated PS ratios are considered overvalued.